Most biotechs are build on promise of buyout which is based on peak revenue in future
If BO does not happen early - co needs to build the sales and marketing channels to generate revenue - most small co do not have that kind of skills and manpower - building such capability means a lot of initial costs and the anxious period of start to do actual sales - this is where the disappointments start and SP goes down